Short Interest in Bionano Genomics, Inc. (NASDAQ:BNGO) Rises By 11.4%

Bionano Genomics, Inc. (NASDAQ:BNGO) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 17,650,000 shares, a growth of 11.4% from the December 15th total of 15,840,000 shares. Based on an average trading volume of 6,670,000 shares, the short-interest ratio is currently 2.6 days. Approximately 12.7% of the company’s stock are short sold.

Institutional Trading of Bionano Genomics

Institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP bought a new position in shares of Bionano Genomics during the third quarter worth about $46,000. Geode Capital Management LLC grew its position in shares of Bionano Genomics by 47.3% during the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after acquiring an additional 283,639 shares during the last quarter. Armistice Capital LLC bought a new position in shares of Bionano Genomics during the second quarter worth about $1,138,000. Finally, Carret Asset Management LLC grew its position in shares of Bionano Genomics by 89.0% during the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after acquiring an additional 40,055 shares during the last quarter. 11.35% of the stock is owned by institutional investors and hedge funds.

Bionano Genomics Stock Down 5.9 %

Shares of NASDAQ:BNGO traded down $0.01 on Friday, reaching $0.19. 7,196,647 shares of the company’s stock were exchanged, compared to its average volume of 13,889,912. Bionano Genomics has a fifty-two week low of $0.18 and a fifty-two week high of $1.40. The business’s 50-day moving average is $0.24 and its two-hundred day moving average is $0.38. The company has a quick ratio of 0.99, a current ratio of 1.43 and a debt-to-equity ratio of 0.07.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH cut shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Friday, November 15th.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.